Back to search
Thalassemia Major With Severe Transfusional Iron Overload
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Thalassemia Major With Severe Transfusional Iron Overload trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Thalassemia Major With Severe Transfusional Iron Overload trials you may qualify forWe hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and…
In this 4-year extension study the safety, efficacy and and pharmacokinetics of deferasirox in regularly transfused pediatric patients with β-thalassemia major…
Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a resul…
The purpose of this open-label, non-comparative, multi-center protocol was to further evaluate safety and to provide treatment with ICL670 to patients who had o…
Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatmen…
To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially availa…